Liraglutide linked to reduction in VAT and improvement in beta-index
For obese individuals with prediabetes or early type 2 diabetes, liraglutide is associated with a greater reduction in visceral adipose tissue (VAT) and greater improvement inβ-index, according to a study inDiabetes Care.Medical Xpress (Source: Society for Endocrinology)
Source: Society for Endocrinology - September 27, 2017 Category: Endocrinology Source Type: news
Mayo study shows drug slows stomach emptying, may individualize obesity treatment
(Mayo Clinic) Liraglutide injection, a prescription medication used to treat type 2 diabetes and obesity is associated with marked slowing of stomach emptying and is an effective weight loss therapy. These are the findings of a randomized, double-blind, placebo-controlled study by Mayo Clinic researchers published today in The Lancet Gastroenterology& Hepatology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 25, 2017 Category: International Medicine & Public Health Source Type: news
Mayo study shows drug slows stomach emptying, may individualize obesity treatment
ROCHESTER, Minn. ??Liraglutide injection, a prescription medication used to treat type-2 diabetes and obesity is associated with marked slowing of stomach emptying and is an effective weight loss therapy. These are the findings of a randomized, double-blind, placebo-controlled study by Mayo Clinic researchers published today in The Lancet Gastroenterology& Hepatology. ?Our paper shows that [...] (Source: Mayo Clinic Minnesota News)
Source: Mayo Clinic Minnesota News - September 25, 2017 Category: Hospital Management Source Type: news
Novo Nordisk Settles U.S. Probe Over Diabetes Drug for Nearly $58.7 Mln Novo Nordisk Settles U.S. Probe Over Diabetes Drug for Nearly $58.7 Mln
Novo Nordisk will pay nearly $58.7 million to resolve claims the drugmaker ' s sales staff downplayed the importance of U.S. Food and Drug Administration-mandated warnings about the cancer risks of its diabetes medication Victoza (liraglutide).Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 6, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news
Nordisk settles DOJ ’ s Victoza marketing suit for $59m
Novo Nordisk (NYSE:NVO) said yesterday afternoon that it inked a $58.7 million deal with the U.S. Dept. of Justice to settle an investigation into the company’s marketing practices for Victoza – its Type II diabetes drug.
The agreement settles eight different lawsuits alleging that the drugmaker misled doctors by dressing salespeople as medical educators, paying physicians to prescribe its liraglutide drug and downplaying the medicine’s side effects.
Get the full story at our sister site, Drug Delivery Business News.
The post Nordisk settles DOJ’s Victoza marketing suit for $59m appeared first on MassDevice....
Source: Mass Device - September 6, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations Legal News Pharmaceuticals Wall Street Beat Novo Nordisk Source Type: news
Novo Nordisk settles U.S. probe over diabetes drug for nearly $58.7 million
(Reuters) - Novo Nordisk will pay nearly $58.7 million to resolve claims the drugmaker's sales staff downplayed the importance of a warning about cancer risks on the label of its diabetes medication Victoza, the U.S. Justice Department said on Tuesday. (Source: Reuters: Health)
Source: Reuters: Health - September 5, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
Liraglutide Reduces Renal Risks in Type 2 Diabetes (FREE)
By Amy Orciari Herman
Edited by Susan Sadoughi, MD, and Richard Saitz, MD, MPH, FACP, DFASAM
Liraglutide — a glucagon-like peptide 1 (GLP-1) agonist — lowers risks for kidney disease in patients with type 2 diabetes, according to a secondary analysis from an … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - August 30, 2017 Category: Primary Care Source Type: news
Victoza ® reduces the risk of major cardiovascular events in people with type 2 diabetes with or without prior events
A new analysis of the landmark LEADER trial shows that Victoza® (liraglutide) reduced the risk of major cardiovascular (CV) events in people with type 2 diabetes at high CV risk, irrespective of their history of having a heart attack and/or stroke or not having any of these events, when compared to placebo.(1) This post-hoc analysis was presented today at the European Society of Cardiology (ESC) Annual Congress in Barcelona, Spain. (Source: World Pharma News)
Source: World Pharma News - August 28, 2017 Category: Pharmaceuticals Tags: Featured Novo Nordisk Business and Industry Source Type: news
Liraglutide Indicated to Reduce Risk for Cardiovascular Events (FREE)
By Kelly Young
Edited by Susan Sadoughi, MD, and Andr é Sofair, MD, MPH
The type 2 diabetes drug liraglutide (Victoza) has received a new indication, … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - August 28, 2017 Category: Primary Care Source Type: news
D.C. Week: Trump Pressures Congress on ACA Repeal
(MedPage Today) -- Also, FDA okays new indication for diabetes drug liraglutide (Victoza) (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - August 26, 2017 Category: American Health Source Type: news
Victoza (liraglutide) is Approved to Reduce the Risk of Three Major Adverse Cardiovascular Events in Type 2 Diabetes Patients
PLAINSBORO, N.J., Aug. 25, 2017 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved a new indication for Victoza (liraglutide) to reduce the risk of major adverse cardiovascular (CV) events, heart attack, stroke and CV death, in... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 25, 2017 Category: Drugs & Pharmacology Source Type: news
FDA Grants Liraglutide Cardiovascular Events Indication FDA Grants Liraglutide Cardiovascular Events Indication
Liraglutide becomes the second glucose-lowering drug, after empagliflozin, to receive an additional indication for cardiovascular risk reduction.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 25, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Alert Source Type: news
Another Diabetes Drug Scores Heart Indication
(MedPage Today) -- Liraglutide follows empagliflozin into cardiovascular approval (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - August 25, 2017 Category: Urology & Nephrology Source Type: news
FDA clears Nordisk ’s Victoza as only Type II diabetes drug to cut cardio risks
The FDA approved a new indication for Novo Nordisk‘s (NYSE:NVO) Victoza liraglutide injection, clearing it as the only Type II diabetes medication indicated to reduce the risk of cardiovascular diseases, like heart attack and stroke.
The regulatory watchdog’s decision is based on results from Nordisk’s 9,300-patient Leader trial, which showed that Victoza significantly reduced the risk of cardiovascular death, non-fatal heart attack and non-fatal stroke.
Get the full story at our sister site, Drug Delivery Business News.
The post FDA clears Nordisk’s Victoza as only Type II diabetes drug to cut cardio risks appear...
Source: Mass Device - August 25, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Cardiovascular Diabetes Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Regulatory/Compliance Wall Street Beat Novo Nordisk Source Type: news
In Europe, Changes to Liraglutide Label to Reflect LEADER In Europe, Changes to Liraglutide Label to Reflect LEADER
Product labeling of Saxenda has been changed and a new indication endorsed for Victoza, both reflecting liraglutide ' s cardiovascular event reduction potential.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 28, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
